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Glioblastomas frequently harbour genetic lesions that
stimulate the activity of mammalian target of rapamy-
cin complex 1 (mTORC1). Loss of heterozygosity of
tuberous sclerosis complex 1 (TSC1) or TSC2, which
together form a critical negative regulator of
mTORC1, is also seen in glioblastoma; however, it is
not known how loss of the TSC complex affects the
development of malignant gliomas. Here we investi-
gated the role of Tsc1 in gliomagenesis in mice. Tsc1
deﬁciency up-regulated mTORC1 activity and sup-
pressed the proliferation of neural stem/progenitor
cells (NSPCs) in a serial neurosphere-forming assay,
suggesting that Tsc1-deﬁcient NSPCs have defective
self-renewal activity. The neurosphere-forming cap-
acity of Tsc1-deﬁcient NSPCs was restored by
p16Ink4ap19Arf deﬁciency. Combined Tsc1 and
p16Ink4ap19Arf deﬁciency in NSPCs did not cause glio-
magenesis in vivo. However, in a glioma model driven
by an active mutant of epidermal growth factor recep-
tor (EGFR), EGFRvIII, loss of Tsc1 resulted in an
earlier onset of glioma development. The mTORC1
hyperactivation by Tsc1 deletion accelerated malignant
phenotypes, including increased tumour mass and
enhanced microvascular formation, leading to intracra-
nial haemorrhage. These data demonstrate that,
although mTORC1 hyperactivation itself may not be
sufﬁcient for gliomagenesis, it is a potent modiﬁer of
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Glioblastoma (GBM) is the most common high-grade
malignant glioma in humans. GBM is categorized as a
WHO grade IV astrocytoma, a very aggressive, inva-
sive and destructive brain tumour (1). Primary GBM
arises de novo in the absence of pre-existing low-grade
lesions, whereas secondary GBM develops progres-
sively from low-grade astrocytomas, generally over a
period of 510 years. Alterations in several signalling
pathways are associated with gliomagenesis, including
the RTK/RAS/PI3K pathway and the p53 and retino-
blastoma tumour suppressor pathways (2).
Mammalian target of rapamycin (mTOR) is a
serine/threonine protein kinase that belongs to the
PI3K-related kinase family and participates in two
complexes, designated mTOR complex 1 (mTORC1)
and 2 (mTORC2). mTOR regulates tumorigenesis by
controlling multiple cellular processes, including pro-
tein synthesis, glucose metabolism, fatty acid and
sterol synthesis, and autophagy (3). mTORC1 is a
multi-protein complex composed of Raptor, mTOR,
LST8 and PRAS40, and it is activated by growth fac-
tors and cytokines. A heterodimer of tuberous sclerosis
complex (TSC) 2 (also known as tuberin) and TSC1
(also known as hamartin) exhibits GTPase activating
protein (GAP) activity towards RHEB, an activator of
mTORC1, and therefore, negatively regulates
mTORC1. Activation of PI3K via RTKs leads to
activation of AKT (also known as protein kinase B).
AKT phosphorylates TSC2 and blocks the GAP activ-
ity of the TSC complex. The TSC complex can also be
inactivated by the RAS-ERK pathway. In GBM,
RTK/RAS/PI3K signalling is frequently altered by
genetic mutations, including ampliﬁcation and alter-
ation of the epidermal growth factor receptor (EGFR)
gene or NF1 deletion (2). Thus, malignant gliomas
frequently harbour genetic lesions that stimulate the
activity of mTORC1.
Mutations in either TSC1 or TSC2 cause tuberous
sclerosis, a multi-system genetic disorder that is char-
acterized by tumour or hamartoma formation and
neurological manifestations mediated by hyperactiva-
tion of the mTOR pathway (4, 5). Brain lesions,
including cortical tubers, subependymal nodules
(SENs) and subependymal giant cell astrocytomas
J. Biochem. 2014;155(4):227–233 doi:10.1093/jb/mvt112






















(SEGAs) have been observed in TSC patients. Tsc1
deletion in embryonic telencephalic neural stem/
progenitor cells (NSPCs) has been reported to cause
TSC neuropathological lesions, such as SENs (6).
Postnatal deletion of Tsc1 in NSPCs of tamoxifen
(TAM)-inducible Nestin-CreERT2 transgenic mice
leads to development of SEGAs, as well as SEN-like
structures (7). In addition, loss of heterozygosity of
TSC1 or TSC2 has been found in GBM, although
the frequency is relatively rare (8). However, whether
loss of the TSC complex affects malignant gliomagen-
esis is not known.
In this study, we investigated the effects of Tsc1 de-
letion on NSPCs and gliomagenesis. Tsc1 deﬁciency
inhibited the self-renewal of NSPCs via activation of
tumour suppressors. Although Tsc1 deﬁciency was not
sufﬁcient for gliomagenesis, it accelerated glioma
development and enhanced malignant properties in a
glioma model. Thus, increased mTORC1 activity




Rosa26-CreERT2 mice were kindly provided by Dr Tyler Jacks
(Massachusetts Institute of Technology) (9). p16Ink4aþ/p19Arfþ/
mice were obtained from the Mouse Models of Human Cancers
Consortium of NCI-Frederick (10). Tsc1f/f mice were purchased
from Jackson Laboratory. BALB/c nu/nu mice used as recipients
were purchased from Sankyo Labo Service. All animal experiments
were approved by the Committee on Animal Experimentation of
Kanazawa University and performed in compliance with the
University’s Guidelines for the Care and Use of Laboratory
Animals.
Primary NSPC culture
To culture primary NSPCs, subventricular zone (SVZ) regions were
harvested from brains of 4-week-old male mice. After mechanical
dissociation, cells were cultured in Coaster Ultra-low attachment
plates (Corning) in DMEM/F12 (Life Technologies) containing
B27 (Life Technologies), 20 ng/ml human FGF2 (Wako), 20 ng/ml
human EGF (Sigma) and penicillin/streptomycin (Life
Technologies) for 7 days, then treated with 0.1 mM 4-hydroxy
TAM (4-OHT, Sigma) for 3 days to activate Cre recombinase,
followed by removal of 4-OHT by washing.
Sphere-forming assay
The cultured primary NSPCs were dissociated with Accutase
(Life technologies) and ﬁltered through a 40-mm cell strainer (BD
Biosciences). The dissociated cells in single-cell suspension (300 cells/
200ml) were cultured in a 96-well Coaster Ultra-low attachment plate
in the same medium containing 1% methylcellulose (Wako) for
7 days. These primary spheres that larger than 50 mm in diameter
were counted. For the serial sphere-forming assays, the formed
spheres were dissociated with Accutase and again cultured for
7 days in the same conditions.
Retrovirus preparation and infection
pLERNL-human EGFRvIII was a kind gift from Dr Frank Furnari
(University of North Carolina). The digested human EGFRvIII seg-
ment was subcloned into pGCDNsamIREShuKO, which was pro-
vided by Dr Masafumi Onodera (National Research Institute for
Child Health and Development) (11). Cells of the Plat-E packaging
line, a gift from Dr Toshio Kitamura (The Institute of Medical
Science University of Tokyo), were transfected with this construct,
and retrovirus-containing supernatants were concentrated by centri-
fugation at 6,000g for 16 h. The cultured primary NSPCs were
infected with the retroviruses for 24 h and then cultured until
transplantation.
Intracranial inoculation
EGFRvIII-transduced NSPCs were dissociated and re-suspended in
5% FBS/PBS at a concentration of 104 cells/ml. The cells were trans-
planted into anesthetized 4-week-old female Balb/c nu/nu mice as
described previously (12).
Immunohistological analysis
Mice were deeply anesthetized with pentobarbital and then perfused
with 4% paraformaldehyde (PFA). Dissected brain samples were
soaked in 4% PFA overnight and embedded in parafﬁn. The sam-
ples were sectioned into 5-mm slices, and antigens were reactivated
with target retrieval solution (Dako). The following primary anti-
bodies were used: anti-human EGFR (Thermo Fisher Scientiﬁc),
pS6(S235/236) (Cell Signaling Technologies), p4E-BP1(T34/46)
(Cell Signaling Technologies), Ki-67 (BD Biosciences), VEGF-A
(Santa Cruz Biotechnologies) and CD34 (Abcam). Signals were
visualized with horseradish peroxidase (HRP)-conjugated secondary
antibodies (GE Healthcare). ImPACT 3,30-diaminobenzidine (DAB)
(Vector laboratories) was used for DAB staining of tumour sections,
which were counterstained with Mayer’s haematoxylin (Wako). For
haematoxylin and eosin (H&E) staining, sections were stained with
Mayer’s H&E solution (Wako). Histological analysis of tumour spe-
cimens was performed using BZ-9000 (Keyence) and Axio Imager
A1 (Carl Zeiss) microscopes.
Western blotting
Proteins were extracted with lysis buffer (0.1M Tris [pH 6.7], 4%
SDS, phosphatase inhibitor (Thermo Fisher Scientiﬁc), complete
mini (Roche)) and quantiﬁed using a bicinchoninic acid (BCA) pro-
tein assay kit (Thermo). Protein (5 mg) was loaded, and the separated
proteins were transferred onto 0.45-mm polyvinylidene diﬂuoride
(PVDF) membranes (Millipore), which were blocked in 5% (w/v)
BSA/0.02% (v/v) Tween 20/PBS and incubated with primary anti-
bodies overnight at 4C, followed by incubation with HRP-conju-
gated antibodies (GE Healthcare) and detection with ECL Prime
(GE Healthcare).
Administration of rapamycin
Rapamycin (LC Laboratories) was resuspended in 5% (v/v) Tween
80/5% (v/v) PEG400 in PBS, and 20mg/kg was administered by
intraperitoneal injection.
Statistical analysis
Student’s t-test and log-rank test were performed with Prism6. All
P-values were two-tailed, and P50.05 was considered signiﬁcant.
Data are shown as mean SD.
Results
Loss of Tsc1 inhibits the sphere-forming capacity
of NSPCs
To investigate the role of mTORC1 in the self-renewal
of NSPCs, we performed a neurosphere-forming assay
using Tsc1-deﬁcient NSPCs. We generated Tsc1f/f;
Rosa26-CreERT2 (Tsc1f/fCreER) mice, in which Tsc1
could be depleted in all tissues by a TAM-
inducible Cre-loxP system. We isolated NSPCs derived
from the SVZ in the brains of these or control Tsc1þ/þ
CreER mice and cultured them in standard media for
neurosphere formation, which included EGF
and FGF2 without serum. The deletion of Tsc1 by
treatment of NSPCs with 4-OHT did not affect the
number or size of primary neurospheres (Fig. 1A,
Supplementary Fig. S1A). However, in secondary and
tertiary neurosphere assays, Tsc1-deﬁcient NSPCs
formed fewer spheres than control NSPCs. In the qua-
ternary assay, control cells still had sphere-forming cap-
acity, whereas Tsc1-deﬁcient cells did not, indicating
that the self-renewal of NSPCs is inhibited by Tsc1 de-
letion in vitro (Fig. 1A). Because mTORC1













hyperactivation is reported to induce senescence
by activating tumour suppressors, including p53,
p16Ink4a and p19Arf, we further generated Tsc1f/
fCreER mice in a p16Ink4ap19Arf-deﬁcient background.
As previously reported (13), loss of p16Ink4ap19Arf
increased sphere formation compared with wild type
and reversed the inhibitory effect of Tsc1 deﬁciency
on NSPCs (Fig. 1B, Supplementary Fig. S1B). The
4-OHT did not affect sphere formation of the corres-
ponding control Tsc1þ/þCreER cells (Fig. 1C and D,
Supplementary Fig. S1C and D). Depletion of
Tsc1 protein increased phosphorylation of S6 and
p70S6K, indicating mTORC1 activation in Tsc1-
deﬁcient NSPCs (Fig. 1E). These data suggest that
mTORC1 hyperactivation inhibits the self-renewal cap-
acity of NSPCs by activating p16Ink4ap19Arf.
Loss of Tsc1 is not sufficient for gliomagenesis
Because p16Ink4ap19Arf deﬁciency reversed the inhibi-
tory effect of mTORC1 activation on NSPC prolifer-
ation, we hypothesized that Tsc1 deletion in
combination with p16Ink4ap19Arf deﬁciency induces
gliomagenesis. Therefore, we inoculated Tsc1f/fCreER
neurosphere cells (p16Ink4ap19Arf-deﬁcient background)
into the basal ganglia of immunocompromised mice,
followed by administration of TAM to induce Tsc1
deletion. However, no mice inoculated with control
or Tsc1-deﬁcient neurospheres showed symptoms of
glioma development within 5 months (Fig. 2A). Like
Tsc1 deﬁciency, the constitutively active EGFR
mutant (EGFRvIII) increased mTORC1 activity
in neurospheres (Fig. 2B). Most recipients
inoculated with p16Ink4ap19Arf-deﬁcient neurosphere
cells transduced with EGFRvIII gene developed gli-
omas, as reported previously (14). Therefore, the loss
of Tsc1 by itself may not be sufﬁcient for gliomagenesis
even in a p16Ink4ap19Arf-deﬁcient background in this
experimental setting.
Loss of Tsc1 accelerates glioma development
Next we examined the effects of Tsc1 deletion on
tumour development using the EGFRvIII-driven
glioma model. Tsc1f/fCreER (p16Ink4a/p19Arf/
background) neurosphere cells were infected with a
retrovirus carrying EGFRvIII and used to inoculate
mouse brains. We then administered TAM to the
mice to delete Tsc1 only in glioma cells in vivo. Mice
injected with vehicle (corn oil) developed gliomas
as early as 5 weeks after transplantation (Fig. 3A).
However, mice injected with Tsc1-deﬁcient glioma
cells began to develop tumours from 4 weeks after
transplantation, and all died within 5 weeks
(Fig. 3A). Genomic analysis revealed that the Tsc1
allele was completely deleted in glioma tissues in vivo
(Fig. 3B). Because TAM administration did not affect
the survival of control Tsc1þ/þCreER gliomas
(Supplementary Fig. S2), the earlier onset was caused
by Tsc1 deletion, not by Cre recombinase or TAM
itself. Anti-human EGFR immunostaining showed
that tumour mass increased remarkably in the absence
of Tsc1 (Fig. 3C). Tsc1-deﬁcient gliomas showed
higher expression of pS6, p4E-BP1 and Ki-67 than
controls (Fig. 3D), suggesting that mTORC1 hyperac-







































































































Fig. 1 mTORC1 hyperactivation by Tsc1 deletion suppresses NSPC sphere formation through p16Ink4a/p19Arf. (AD) Serial sphere formation
assay. Dissociated Tsc1f/fCreER NSPCs (A) or Tsc1f/fp16Ink4a/p19Arf/CreER NSPCs (B) treated with or without 4-OHT were cultured at
low density to evaluate their sphere-forming abilities. Tsc1þ/þCreER NSPCs (C) and Tsc1þ/þp16Ink4a/p19Arf/CreER NSPCs (D) were
cultured as controls to evaluate the effect of 4-OHT or Cre. Data shown are the mean sphere number SD (n¼ 3). ***P50.001 (Student’s
t-test). Tsc1-deﬁcient cells did not form any spheres in the quaternary assay in (A). (E) Phosphorylation of mTORC1 downstream targets in
NSPCs. Lysates were prepared from primary culture of Tsc1f/f p16Ink4a/p19Arf/CreER NSPCs with or without 4-OHT and subjected to
western blotting.














phenotypes in Tsc1-deficient gliomas
Gliomas lacking Tsc1 showed obvious hemorrhagic re-
gions (Fig. 4A and B). Because robust angiogenesis is
an important histological hallmark of GBM, we used a
CD34 antibody to examine microvasculature forma-
tion. Tsc1 deﬁciency increased the number of CD34þ
cells with a microvasculature appearance (Fig. 4C) and
the expression of VEGF (Fig. 4D), suggesting that
up-regulation of VEGF promoted microvasculature
formation in the gliomas. Thus, by enhancing the
microvasculature, mTORC1 hyperactivation may pro-
mote cell proliferation and accelerate glioma develop-
ment in combination with oncogenic signals in vivo.
To investigate the link between mTORC1 hyperac-
tivation and the malignant phenotypes of Tsc1f/
fCreERþTAM gliomas, we administered rapamycin, an
allosteric mTORC1 inhibitor, to mice with Tsc1f/
fCreER and Tsc1f/fCreERþTAM gliomas. Rapamycin
signiﬁcantly prolonged survival in mice with both
types of glioma, with no signiﬁcant difference in sur-
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Fig. 3 Acceleration of EGFRvIII-driven glioma development by Tsc1-deﬁciency. (A) Effect of Tsc1 deletion on survival of mice bearing
EGFRvIII-driven gliomas. The mice were intracranially inoculated with EGFRvIII-transduced Tsc1f/f p16Ink4a/p19Arf/CreER NSPCs and
then administered TAM. KaplanMeier analysis and the log-rank test were used to assess the effect of Tsc1 deletion on tumour latency.
(B) Deletion efﬁciency of Tsc1 by TAM in glioma tissues. Genomic DNA was isolated from glioma tissues and evaluated by PCR analysis. Plus
symbol , f, and triangle symbol indicate wild-type, ﬂoxed, and deleted allele of Tsc1, respectively. (CD) Immunohistological analysis of control
and Tsc1-deﬁcient (þTAM) gliomas. Tissue sections of gliomas were stained with antibodies against the indicated molecules. Scale bars¼ 1mm































EGFRvIII  p16Ink4a-/- p19Arf-/- (n=5)
Tsc1f/f  p16Ink4a-/- p19Arf-/-  CreER (n=5)
Tsc1f/f  p16Ink4a-/- p19Arf-/-  CreER+TAM (n=5)
B
Fig. 2 mTORC1 hyperacvation is not sufﬁcient for gliomagenesis. (A) Effects of Tsc1 deﬁciency or EGFRvIII overexpression on survival of
mice inoculated with p16Ink4a/p19Arf-deﬁcient NSPCs. Mice were intracranially inoculated with Tsc1-deﬁcient NSPCs isolated from Tsc1f/f
p16Ink4a/p19Arf/CreERmice and then given TAM. For EGFRvIII overexpression, p16Ink4a/p19Arf/NSPCs were infected with retrovirus
carrying EGFRvIII intracranially inoculated into immunocompromised mice. (B) Lysates were prepared from primary cultures of
EGFRvIII-transduced p16Ink4a/p19Arf/ NSPCs and subjected to western blotting with antibodies against the indicated proteins.













treatment decreased S6 phosphorylation and expres-
sion of Ki-67 and dramatically diminished VEGF
expression and the CD34þ microvasculature in Tsc1-
deﬁcient gliomas (Fig. 5B). These results demonstrate
that mTORC1 hyperactivation due to Tsc1 deﬁciency
accelerates gliomagenesis through enhanced microvas-
culature formation.
Discussion
One of the scientiﬁc questions about malignant gli-
omas is their cell of origin. Experiments with genetic
engineering techniques using mouse models have
clearly shown that gliomas can be derived from fully
differentiated astrocytes and neurons, as well as from
neural stem cells and oligodendro progenitor cells
(1416). On the other hand, glioma cells exhibit
stem-like features and have properties in common
with NSPCs. Therefore, it is worth investigating the
roles of signalling molecules in the self-renewal of
normal NSPCs and gliomagenesis.
Although one previous study reported that Tsc1 de-
letion did not affect NSPC proliferation (7), in another
study Tsc1 deletion resulted in transient expansion of
Tsc1f/f  CreER / Rapamycin(-) (n=4)
Tsc1f/f  CreER / Rapamycin(+) (n=4)
Tsc1f/f  CreER+TAM / Rapamycin(-) (n=4)
Tsc1f/f  CreER+TAM / Rapamycin(+) (n=4)

































Fig. 5 Reversal of malignant phenotypes in Tsc1-deﬁcient gliomas by rapamycin. (A) Effects of rapamycin on the latency of Tsc1f/fCreER and
Tsc1f/fCreERþTAM gliomas. Mice were treated with rapamycin (20mg/kg) or vehicle from Day 12 until death. Cre activity was induced by TAM
injection. **P50.01 (log-rank test). (B) Representative immunohistochemistry of tumour regions from Tsc1f/fCreERþTAM gliomas. Sections












Tsc1f/f  CreER Tsc1f/f  CreER+TAM
Tsc1f/f  CreER Tsc1f/f  CreER+TAM
Fig. 4 Enhancement of intratumour haemorrhage through increased microvascular formation due to Tsc1 deﬁciency. (A, B) H&E staining of
control (A) and Tsc1-deﬁcient (B) gliomas. Scale bar¼ 1mm (left), 0.5mm (inset). (C, D) Immunohistological analysis of CD34 (C) or VEGF
(D) in control and Tsc1-deﬁcient gliomas. The sections were counterstained with haematoxylin. Scale bars¼ 50 mm.













NSPCs followed by premature differentiation and
reduced self-renewal (6). Furthermore, a recent study
reported that mTORC1 activation by RHEB overex-
pression promoted the differentiation of neural stem
cells to transient-amplifying cells at the expense of
their self-renewal (17). Although these inconsistent re-
sults may be due to differences in assay methodology,
it remains unclear how mTORC1 activity regulates the
behavior of normal NSPCs. Our data suggest that
mTORC1 activates the p16Ink4a and p19Arf tumour
suppressors in NSPCs, causing defects in self-renewal.
Because the defective phenotypes of Tsc1-deﬁcient
NSPCs affected secondary or tertiary, but not primary,
sphere formation, loss of Tsc1 may cause serious dam-
ages to the self-renewal capacity of neural stem cells,
but not to the proliferation of progenitors.
In GBM, mutations in genes encoding molecules up-
stream of mTORC1 are presumed to induce its hyper-
activation (2). Glioma patients with high mTORC1
activity show poor prognosis (18, 19). However,
mTOR inhibitors (rapamycin and its analogs) have
failed to show signiﬁcant beneﬁcial effects in patients
with GBM (20, 21). Therefore, it has not been clear
whether mTORC1 activation is a bona ﬁde driver of
gliomagenesis. Although Pten deﬁciency or Ras activa-
tion, which induce mTORC1 activation, cause glioma
development in mouse models (22, 23), these signals
also stimulate signal transduction pathways other
than mTORC1. In this study, we demonstrated that,
although mTORC1 hyperactivation accelerates glioma
formation and enhances the malignant phenotype in a
glioma model, it is not sufﬁcient for gliomagenesis. In
this experimental setting, the immunocompromised-
recipient mice occasionally died 6 months after trans-
plantation for reasons not associated with gliomas
(presumably infections). Therefore, it is possible that
the mice would develop gliomas at later time points,
but this would likely require additional aberrant sig-
nals caused by gene mutations that occur with long
latency. Thus, mTORC1 hyperactivation is a potent
modiﬁer, but not an initiator, of malignant gliomas.
Aberrant vasculature associated with enhanced
angiogenesis is one of the histological hallmarks of
GBM, because a sufﬁcient supply of nutrients and
oxygen is required for rapidly growing tumours (24).
Rapamycin inhibits angiogenesis and VEGF produc-
tion in a mouse metastatic colon cancer model (25),
and Tsc2 deﬁciency induces VEGF production in
ﬁbroblasts (26), suggesting that hyperactivation of
mTORC1 causes VEGF production in tumour cells,
resulting in enhanced angiogenesis. Consistent with
these data, we also found that mTORC1 hyperactiva-
tion promoted microvasculature formation, stimulat-
ing glioma proliferation. Thus, mTORC1 activation
may support glioma development not only in a cell-
autonomous manner but also by affecting the
surrounding environment.
Although mTORC1 inhibition by rapamycin signiﬁ-
cantly suppressed gliomas, all mice in our study even-
tually died of glioma development. One reason is that
the presence of rapamycin-insensitive mTOR sub-
strates limits the ability of rapalogs to completely
inhibit mTORC1 targets (27, 28). ATP-competitive
mTOR inhibitors have been developed and reportedly
show more cytotoxic effects, and recently NVP-
BEZ235, a PI3K/mTOR inhibitor, was found to be
effective in a xenograft glioma model (29). However,
it is still unclear whether complete inhibition of
mTORC1 activity leads to eradication of glioma cells
in vivo, because we have recently reported that leuke-
mia stem cells can survive and proliferate in an
mTORC1-independent manner (30). A detailed ana-
lysis of gliomas by using a genetic approach to inhibit-
ing mTORC1 and mTORC2 would contribute to the
identiﬁcation of novel targets for GBM therapy.
Supplementary Data
Supplementary Data are available at JB Online.
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